Savara to Present at the Cantor Fitzgerald 2017 Global Healthcare Conference on September 27th
AUSTIN, TX -- (Marketwired) -- 09/21/17 --
Savara Inc.
(NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the Cantor Fitzgerald 2017 Global Healthcare Conference on Wednesday September 27, 2017 at 11:30 a.m. Eastern Time at the InterContinental New York Barclay Hotel in New York.
Interested parties can access a live audio webcast on the Savara web site at www.savarapharma.com. An archived presentation will be available on the web site for 30 days.
About Savara
Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara's pipeline comprises: Molgradex, a Phase III stage inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, for PAP; AeroVanc, a Phase III stage inhaled vancomycin for treatment of MRSA infection in Cystic Fibrosis; and, Aironite, an inhaled sodium nitrite for HFpEF in Phase II development. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma).
Savara may announce material information about its finances, product candidates, clinical trials and other matters to its investors using its investor relations website (http://savarapharma.com/investors), SEC filings, press releases, public conference calls and webcasts. Savara uses these channels, as well as social media, to communicate with its stockholders and the public about the company and other issues. It is possible that the information Savara posts on its website and social media could be deemed to be material information. Therefore, Savara encourages investors, the media, and others interested in the company to review the information Savara posts on its investor relations website (referenced above) and any social media channels listed on its website from time to time.
Contacts:
Savara Inc.
Ioana C. Hone
(ir@savarapharma.com)
(512) 961-1891
The Trout Group
Kelly Mueller
(kmueller@troutgroup.com)
(646) 378-2965
Source: Savara Inc.
